What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals
Analysts have provided the following ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter:
|Last 30 Days||1 Month Ago||2 Months Ago||3 Months Ago|
In the last 3 months, 11 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company has an average price target of $258.91 with a high of $307.00 and a low of $205.00.
This current average has decreased by 6.28% from the previous average price target of $276.27.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts can recommend “buy”, “sell”, “hold”, or similar verbage for each stock based on that company’s recent performance. “Buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and is a recommendation to purchase the stock. On the other hand, “Sell” implies that an analyst forecasts a downwards trend for the stock. “Hold” suggests that investors should maintain their positions on that stock because of forecasted stagnation or lack of new information.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.